{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:32:09Z","timestamp":1789421529794,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      We conducted a cost-effectiveness analysis in which we compared a preoperative [\n                      <jats:sup>18<\/jats:sup>\n                      F]Fluorocholine PET\/CT-based one-stop-shop imaging strategy with current best practice in which [\n                      <jats:sup>18<\/jats:sup>\n                      F]Fluorocholine PET\/CT is only recommended after negative or inconclusive [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-methoxy isobutyl isonitrile SPECT\/CT for patients suffering from primary hyperparathyroidism. We investigated whether the one-stop-shop strategy performs as well as current best practice but at lower costs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We developed a cohort-level state transition model to evaluate both imaging strategies respecting an intraoperative parathyroid hormone monitored treatment setting as well as a traditional treatment setting. The model reflects patients\u2019 hospital journeys after biochemically diagnosed primary hyperparathyroidism. A cycle length of twelve months and a lifetime horizon were used. We conducted probabilistic analyses simulating 50,000 cohorts to assess joint parameter uncertainty. The incremental net monetary benefit and cost for each quality-adjusted life year were estimated. Furthermore, threshold analyses regarding the tariff of [\n                      <jats:sup>18<\/jats:sup>\n                      F]Fluorocholine PET\/CT and the sensitivity of [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-methoxy isobutyl isonitrile SPECT\/CT were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The simulated long-term health effects and costs were similar for both imaging strategies. Accordingly, there was no incremental net monetary benefit and the one-stop-shop strategy did not result in lower costs. These results applied to both treatment settings. The threshold analysis indicated that a tariff of \u20ac885 for [\n                      <jats:sup>18<\/jats:sup>\n                      F]Fluorocholine PET\/CT was required to be cost-effective compared to current best practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both preoperative imaging strategies can be used interchangeably. Daily clinical practice grounds such as available local resources and patient preferences should inform policy-making on whether a hospital should implement the one-stop-shop imaging strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-024-06771-1","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:01:42Z","timestamp":1717545702000},"page":"3585-3595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cost-effectiveness of one-stop-shop [18F]Fluorocholine PET\/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-0337","authenticated-orcid":false,"given":"Sietse","family":"van Mossel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9654","authenticated-orcid":false,"given":"Sopany","family":"Saing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-9899","authenticated-orcid":false,"given":"Elske","family":"Quak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-2743","authenticated-orcid":false,"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-6766","authenticated-orcid":false,"given":"Dennis","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"6771_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.33","volume":"2","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;2:1\u201316.","journal-title":"Nat Rev Dis Primers"},{"key":"6771_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391:168\u201378.","journal-title":"Lancet"},{"key":"6771_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrendo.2017.104","volume":"14","author":"MD Walker","year":"2018","unstructured":"Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14:115\u201325.","journal-title":"Nat Rev Endocrinol"},{"key":"6771_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145\u201358.","journal-title":"Lancet"},{"key":"6771_CR5","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1210\/jc.2008-2006","volume":"94","author":"E Vignali","year":"2009","unstructured":"Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2306\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"6771_CR6","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/jbmr.4685","volume":"37","author":"Z Ye","year":"2022","unstructured":"Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, Chang Y, et al. The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials. J Bone Miner Res. 2022;37:2351\u201372.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"6771_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s001980050210","volume":"10","author":"P Lips","year":"1999","unstructured":"Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Kellingray S, Leplege A, Liberman UA, McCloskey E, Minne H, Reeve J, Reginster JY, Scholz M, Todd C, de Vernejoul MC, Wiklund I. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int. 1999;10(2):150\u201360. https:\/\/doi.org\/10.1007\/s001980050210.","journal-title":"Osteoporos Int"},{"key":"6771_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00240-020-01238-y","volume":"49","author":"S Tapiero","year":"2021","unstructured":"Tapiero S, Limfuco L, Bechis SK, Sur RL, Penniston KL, Nakada SY, et al. The impact of the number of lifetime stone events on quality of life: results from the North American stone quality of life consortium. Urolithiasis. 2021;49:321\u20136.","journal-title":"Urolithiasis"},{"key":"6771_CR9","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00259-021-05334-y","volume":"48","author":"PP Ov\u010dari\u010dek","year":"2021","unstructured":"Ov\u010dari\u010dek PP, Giovanella L, Gasset IC, Hindi\u00e9 E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021;48:2801\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00259-009-1131-z","volume":"36","author":"E Hindi\u00e9","year":"2009","unstructured":"Hindi\u00e9 E, Ugur \u00d6, Fuster D, O\u2019Doherty M, Grassetto G, Ure\u00f1a P, et al. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009;36:1201\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/MNM.0000000000000595","volume":"37","author":"WP Kluijfhout","year":"2016","unstructured":"Kluijfhout WP, Vorselaars WMCM, Van Den Berk SAM, Vriens MR, Borel Rinkes IHM, Valk GD, et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun. 2016;37:1246\u201352.","journal-title":"Nucl Med Commun"},{"key":"6771_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s00259-017-3911-1","volume":"45","author":"E Quak","year":"2018","unstructured":"Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, et al. F18-choline PET\/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT\/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging. 2018;45:658\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR13","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1007\/s00259-018-4018-z","volume":"45","author":"S Grimaldi","year":"2018","unstructured":"Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET\/CT. Eur J Nucl Med Mol Imaging. 2018;45:1772\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13550-019-0544-3","volume":"9","author":"WAM Broos","year":"2019","unstructured":"Broos WAM, Wondergem M, Knol RJJ, van der Zant FM. Parathyroid imaging with 18F-fluorocholine PET\/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. EJNMMI Res. 2019;9:72.","journal-title":"EJNMMI Res"},{"key":"6771_CR15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1007\/s00259-018-3980-9","volume":"45","author":"M Beheshti","year":"2018","unstructured":"Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, et al. 18F-Fluorocholine PET\/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT\/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging. 2018;45:1762\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2967\/jnumed.119.229914","volume":"61","author":"A Cuderman","year":"2020","unstructured":"Cuderman A, Senica K, Rep S, Hocevar M, Kocjan T, Sever MJ, et al. 18F-fluorocholine PET\/CT in primary hyperparathyroidism: Superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands. J Nucl Med. 2020;61:577\u201383.","journal-title":"J Nucl Med"},{"key":"6771_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2967\/jnumed.120.245993","volume":"62","author":"E Hindi","year":"2021","unstructured":"Hindi E, Schwartz P, Avram AM, Imperiale A, Sebag F, Ta\u00efeb D. Primary Hyperparathyroidism: defining the appropriate preoperative imaging algorithm. J Nucl Med. 2021;62:3\u201312.","journal-title":"J Nucl Med"},{"key":"6771_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-020-02487-y","volume":"71","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, Bacigalupo L, Treglia G, Piccardo A. Will 18 F-fluorocholine PET\/CT replace other methods of preoperative parathyroid imaging? Endocrine. 2020;71:285\u201397.","journal-title":"Endocrine"},{"key":"6771_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoto.2021.0915","volume":"147","author":"SW Lee","year":"2021","unstructured":"Lee SW, Shim SR, Jeong SY, Kim SJ. Direct comparison of preoperative imaging modalities for localization of primary hyperparathyroidism: a systematic review and network meta-analysis. JAMA Otolaryngol-Head Neck Surg. 2021;147:692\u2013706.","journal-title":"JAMA Otolaryngol-Head Neck Surg"},{"key":"6771_CR20","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1210\/jc.2014-2000","volume":"99","author":"R Udelsman","year":"2014","unstructured":"Udelsman R, \u00c5kerstr\u00f6m G, Biagini C, Duh Q-Y, Miccoli P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metabol. 2014;99:3595\u2013606.","journal-title":"J Clin Endocrinol Metabol."},{"key":"6771_CR21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1210\/jc.2012-3168","volume":"98","author":"JW Kunstman","year":"2013","unstructured":"Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab. 2013;98:902\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"6771_CR22","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1002\/cncr.28891","volume":"120","author":"GG Callender","year":"2014","unstructured":"Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. Cancer. 2014;120:3602\u201316.","journal-title":"Cancer"},{"key":"6771_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamasurg.2017.1721","volume":"152","author":"AE Stephen","year":"2017","unstructured":"Stephen AE, Mannstadt M, Hodin RA. Indications for surgical management of hyperparathyroidism: a review. JAMA Surg. 2017;152:878\u201382.","journal-title":"JAMA Surg"},{"key":"6771_CR24","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/jbmr.4682","volume":"37","author":"JP Bilezikian","year":"2022","unstructured":"Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, et al. Management of primary hyperparathyroidism. J Bone Miner Res. 2022;37:2391\u2013403.","journal-title":"J Bone Miner Res"},{"key":"6771_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/bjs.12025","volume":"108","author":"A Bergenfelz","year":"2021","unstructured":"Bergenfelz A, Van Slycke S, Makay \u00d6, Brunaud L. European multicentre study on outcome of surgery for sporadic primary hyperparathyroidism. Br J Surg. 2021;108:675\u201383.","journal-title":"Br J Surg"},{"key":"6771_CR26","first-page":"1465","volume":"10","author":"H Ahmadieh","year":"2020","unstructured":"Ahmadieh H, Kreidieh O, Akl EA, El-Hajj FG. Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults. Cochrane Database Syst Rev. 2020;10:1465\u2013858.","journal-title":"Cochrane Database Syst Rev"},{"key":"6771_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/SLA.0b013e318208fed9","volume":"253","author":"R Udelsman","year":"2011","unstructured":"Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253:585\u201391.","journal-title":"Ann Surg"},{"key":"6771_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.surg.2012.08.022","volume":"152","author":"DF Schneider","year":"2012","unstructured":"Schneider DF, Mazeh H, Sippel RS, Chen H. Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery. 2012;152:1008\u201315.","journal-title":"Surgery"},{"key":"6771_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/SLA.0000000000000207","volume":"259","author":"DF Schneider","year":"2014","unstructured":"Schneider DF, Mazeh H, Chen H, Sippel RS. Predictors of recurrence in primary hyperparathyroidism: an analysis of 1386 cases. Ann Surg. 2014;259:563\u20138.","journal-title":"Ann Surg"},{"key":"6771_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00000658-200004000-00016","volume":"231","author":"PC Smit","year":"2000","unstructured":"Smit PC, Rinkes IHMB, Van Dalen A, Van Vroonhoven TJMV. Direct, minimally invasive adenomectomy for primary hyperparathyroidism: an alternative to conventional neck exploration? Ann Surg. 2000;231:559\u201365.","journal-title":"Ann Surg"},{"key":"6771_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/SLA.0b013e31815c3ffd","volume":"246","author":"J Westerdahl","year":"2007","unstructured":"Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg. 2007;246:976\u201380.","journal-title":"Ann Surg"},{"key":"6771_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00000658-200211000-00001","volume":"236","author":"A Bergenfelz","year":"2002","unstructured":"Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236:543\u201351.","journal-title":"Ann Surg"},{"key":"6771_CR33","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28:2277\u201385.","journal-title":"J Bone Miner Res"},{"key":"6771_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","volume":"20","author":"N Hadker","year":"2014","unstructured":"Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. Endocr Pract. 2014;20:671\u20139.","journal-title":"Endocr Pract"},{"key":"6771_CR35","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, L\u00f8vas K, Debowska A, Eriksen EF, Evang JA, Fossum C, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101:3045\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"6771_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bone.2018.09.017","volume":"120","author":"T Vokes","year":"2019","unstructured":"Vokes T. Quality of life in hypoparathyroidism. Bone. 2019;120:542\u20137.","journal-title":"Bone"},{"key":"6771_CR37","unstructured":"Eurocrine. European Registry for Endocrine Surgery. https:\/\/eurocrine.eu\/about-eurocrine. Accessed February 5. 2024."},{"key":"6771_CR38","unstructured":"R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"6771_CR39","doi-asserted-by":"crossref","unstructured":"Alarid-Escudero F, Knowlton G, Easterly C, Enns EA. Decision Analytic Modeling Package (dampack). R package version 1.0.0; 2021. https:\/\/github.com\/DARTH-git\/dampack.","DOI":"10.32614\/CRAN.package.dampack"},{"key":"6771_CR40","unstructured":"Alarid-Escudero F, Krijkamp E, Pechlivanoglou P, Jalal H, Yang A, Enns E. _darthtools: darthtools is an R package that contains tools developed by the Decision Analysis in R for Technologies in Health (DARTH) workgroup to construct model-based cost-effectiveness analysis in R._; 2024. https:\/\/darth-git.github.io\/darthtools, https:\/\/github.com\/DARTH-git\/darthtools."},{"key":"6771_CR41","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975.","journal-title":"BMJ"},{"key":"6771_CR42","unstructured":"Centraal bureau voor statistiek (CBS). StatLine - Levensverwachting; geslacht, leeftijd. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/37360ned\/table?dl=4CA57. Accessed February 5. 2024."},{"key":"6771_CR43","unstructured":"Dutch Healthcare Authority. Dutch dbc-information system. https:\/\/www.opendisdata.nl. Accessed August 25. 2023."},{"key":"6771_CR44","unstructured":"Dutch Healthcare authority. Dutch drug database. https:\/\/www.medicijnkosten.nl. Accessed August 25. 2023."},{"key":"6771_CR45","unstructured":"Dutch Healthcare Authority. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidzorg. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg. Accessed February 5. 2024."},{"key":"6771_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"M Versteegh","year":"2016","unstructured":"Versteegh M, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health. 2016;19:343\u201352.","journal-title":"Value Health."},{"key":"6771_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","volume":"3","author":"AJ Vickers","year":"2019","unstructured":"Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res. 2019;3:18.","journal-title":"Diagn Progn Res"},{"key":"6771_CR48","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1007\/s00259-022-05794-w","volume":"49","author":"EJ de Koster","year":"2022","unstructured":"de Koster EJ, Vriens D, van Aken MO, Dijkhorst-Oei LT, Oyen WJG, Peeters RP, et al. FDG-PET\/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. Eur J Nucl Med Mol Imaging. 2022;49:3452\u201369.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR49","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clml.2021.11.008","volume":"22","author":"MJE Greuter","year":"2022","unstructured":"Greuter MJE, Eertink JJ, Jongeneel G, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, et al. Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22:382\u201392.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6771_CR50","unstructured":"Ministere des affaires sociales et de la sant\u00e9. D\u00e9crets, arr\u00eat\u00e9s, circulaires textes g\u00e9n\u00e9raux. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000034026295. Accessed February 5. 2024."},{"key":"6771_CR51","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ibd.21862","volume":"18","author":"LE Cipriano","year":"2012","unstructured":"Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn\u2019s disease. Inflamm Bowel Dis. 2012;18:1240\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"6771_CR52","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1089\/thy.2020.0555","volume":"31","author":"R Ciappuccini","year":"2021","unstructured":"Ciappuccini R, Licaj I, Lasne-Cardon A, Babin E, De Raucourt D, Blanchard D, et al. 18F-fluorocholine positron emission tomography\/computed tomography is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: the chocolate study. Thyroid. 2021;31:800\u20139.","journal-title":"Thyroid"},{"key":"6771_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.surg.2021.03.075","volume":"171","author":"A Yap","year":"2022","unstructured":"Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, et al. A cost-utility analysis of 18F-fluorocholine\u2013positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery. 2022;171:55\u201362.","journal-title":"Surgery"},{"key":"6771_CR54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0272989X12454941","volume":"32","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Making. 2012;32:678\u201389.","journal-title":"Med Decis Making"},{"key":"6771_CR55","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices-overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32:667\u201377.","journal-title":"Med Decis Making"},{"issue":"4","key":"6771_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355\u201371. https:\/\/doi.org\/10.2165\/00019053-200624040-00006.","journal-title":"Pharmacoeconomics"},{"key":"6771_CR57","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-018-4123-z","volume":"46","author":"G Treglia","year":"2019","unstructured":"Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:751\u201365.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6771_CR58","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12149-020-01507-1","volume":"34","author":"L Evangelista","year":"2020","unstructured":"Evangelista L, Ravelli I, Magnani F, Iacobone M, Giraudo C, Camozzi V, et al. 18F-choline PET\/CT and PET\/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. Ann Nucl Med. 2020;34:601\u201319.","journal-title":"Ann Nucl Med."},{"key":"6771_CR59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MNM.0000000000000952","volume":"40","author":"WAM Broos","year":"2019","unstructured":"Broos WAM, Van Der Zant FM, Knol RJJ, Wondergem M. Choline PET\/CT in parathyroid imaging: a systematic review. Nucl Med Commun. 2019;40:96\u2013105.","journal-title":"Nucl Med Commun"},{"key":"6771_CR60","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00423-016-1425-0","volume":"401","author":"WP Kluijfhout","year":"2016","unstructured":"Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg. 2016;401:925\u201335.","journal-title":"Langenbecks Arch Surg"},{"key":"6771_CR61","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2967\/jnumed.120.257303","volume":"62","author":"J Whitman","year":"2021","unstructured":"Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA. Assessment and comparison of 18F-Fluorocholine PET and 99mTc-sestamibi scans in identifying parathyroid adenomas: a metaanalysis. J Nucl Med. 2021;62:1285\u201391.","journal-title":"J Nucl Med"},{"key":"6771_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2288-13-12","volume":"13","author":"H Koffijberg","year":"2013","unstructured":"Koffijberg H, van Zaane B, Moons KG. From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling study. BMC Med Res Methodol. 2013;13:12. https:\/\/doi.org\/10.1186\/1471-2288-13-12.","journal-title":"BMC Med Res Methodol"},{"key":"6771_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1472-6963-10-283","volume":"10","author":"A Langer","year":"2010","unstructured":"Langer A. A systematic review of PET and PET\/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res. 2010;10:283. https:\/\/doi.org\/10.1186\/1472-6963-10-283.","journal-title":"BMC Health Serv Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06771-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T02:01:52Z","timestamp":1727748112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06771-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6771"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06771-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from approval by the local ethics committee as it did not include patient data. Instead, all model parameters were obtained from literature evidence or were elicited from an expert panel. No ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}